Premium
Allergic reactions to meglumine antimoniate while treating cutaneous leishmaniasis
Author(s) -
Brasileiro A.,
MartínEzquerra G.,
GarcíaMartinez P.,
Pujol R.M.,
GiménezArnau A.M.
Publication year - 2017
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.13726
Subject(s) - meglumine antimoniate , medicine , humanities , dermatology , cutaneous leishmaniasis , leishmaniasis , art , immunology
secondary to underlying malignancy. Rivaroxaban is an oral direct factor Xa inhibitor currently licenced for use as an anticoagulant in the treatment and prevention of venousthromboembolism, and for prevention of stroke and systemic embolism in non-valvular atrial fibrillation. Previous reports of dermatological side-effects related to rivoraxaban include acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS syndrome). Hypersensitivity reactions were also observed. To our knowledge, there have been no previous reports of rivoraxaban causing cutaneous lupus, photosensitivity or phototoxicity. It is also interesting to note that rivaroxaban has been recently trialled in the management of a small group of patients with thrombotic anti-phospholipid syndrome who may be at greater risk of developing systemic lupus erythematosus.